{
    "root": "d56efbe2-adbe-4ac4-b66c-a74672dd7b58",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Sunitinib Malate",
    "value": "20250131",
    "ingredients": [
        {
            "name": "SUNITINIB MALATE",
            "code": "LVX8N1UT73"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MANNITOL",
            "code": "3OWL53L36A"
        },
        {
            "name": "POVIDONE K30",
            "code": "U725QWY32X"
        },
        {
            "name": "D&C RED NO. 28",
            "code": "767IP0Y5NH"
        },
        {
            "name": "FD&C BLUE NO. 1",
            "code": "H3R47K3TBD"
        },
        {
            "name": "FD&C RED NO. 40",
            "code": "WZB9127XOA"
        },
        {
            "name": "GELATIN, UNSPECIFIED",
            "code": "2G86QN327L"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357"
        },
        {
            "name": "D&C YELLOW NO. 10 ALUMINUM LAKE",
            "code": "CQ3XH3DET6"
        },
        {
            "name": "FD&C BLUE NO. 1 ALUMINUM LAKE",
            "code": "J9EQA3S2JM"
        },
        {
            "name": "FD&C BLUE NO. 2--ALUMINUM LAKE",
            "code": "4AQJ3LG584"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3"
        },
        {
            "name": "FD&C YELLOW NO. 6",
            "code": "H77VEI93A8"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        }
    ],
    "indications": "sunitinib malate capsules kinase inhibitor indicated : treatment adult patients gastrointestinal stromal tumor ( gist ) disease progression intolerance imatinib mesylate . ( 1.1 ) treatment adult patients advanced renal cell carcinoma ( rcc ) . ( 1.2 ) adjuvant treatment adult patients high risk recurrent rcc following nephrectomy . ( 1.3 ) treatment progressive , well-differentiated pancreatic neuroendocrine tumors ( pnet ) adult patients unresectable locally advanced metastatic disease . ( 1.4 )",
    "contraindications": "gist advanced rcc : recommended 50 mg orally daily first 4 weeks 6-week cycle ( schedule 4/2 ) . ( 2.1 ) adjuvant treatment rcc : recommended 50 mg orally daily first 4 weeks 6-week cycle ( schedule 4/2 ) maximum 9 cycles . ( 2.2 ) pnet : recommended 37.5 mg orally daily . ( 2.3 )",
    "warningsAndPrecautions": "12.5 mg capsules hard gelatin capsule maroon opaque cap body , imprinted teva 8199 cap body black ink . available follows : bottles 28 capsules : ndc 0093-8199-28 25 mg capsules hard gelatin capsule light brown opaque cap maroon opaque body , imprinted teva 8224 cap body black ink . available follows : bottles 28 capsules : ndc 0093-8224-28 37.5 mg capsules hard gelatin capsule yellow opaque cap body , imprinted teva 8229 cap body black ink . available follows : bottles 28 capsules : ndc 0093-8229-28 50 mg capsules hard gelatin capsule light brown opaque cap body , imprinted teva 8231 cap body black ink . available follows : bottles 28 capsules : ndc 0093-8231-28 store 20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0f ) ; excursions permitted 15\u00b0 30\u00b0c ( 59\u00b0 86\u00b0f ) [ usp controlled room temperature ] .",
    "adverseReactions": "none .",
    "indications_original": "Sunitinib malate capsules are a kinase inhibitor indicated for: treatment of adult patients with gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate. ( 1.1 ) treatment of adult patients with advanced renal cell carcinoma (RCC). ( 1.2 ) adjuvant treatment of adult patients at high risk of recurrent RCC following nephrectomy. ( 1.3 ) treatment of progressive, well-differentiated pancreatic neuroendocrine tumors (pNET) in adult patients with unresectable locally advanced or metastatic disease. ( 1.4)",
    "contraindications_original": "GIST and Advanced RCC : The recommended dosage is 50 mg orally once daily for the first 4 weeks of each 6-week cycle (Schedule 4/2). ( 2.1 ) Adjuvant Treatment of RCC : The recommended dosage is 50 mg orally once daily for the first 4 weeks of a 6-week cycle (Schedule 4/2) for a maximum of 9 cycles. ( 2.2 ) pNET : The recommended dosage is 37.5 mg orally once daily. ( 2.3 )",
    "warningsAndPrecautions_original": "12.5 mg capsules\n                  Hard gelatin capsule with maroon opaque cap and body, imprinted with TEVA over 8199 on both cap and body in black ink. Available as follows:\n                  Bottles of 28 capsules: NDC 0093-8199-28\n                  25 mg capsules\n                  \n                  Hard gelatin capsule with light brown opaque cap and maroon opaque body, imprinted with TEVA over 8224 on both cap and body in black ink. Available as follows:\n                  Bottles of 28 capsules: NDC 0093-8224-28\n                  37.5 mg capsules\n                  Hard gelatin capsule with yellow opaque cap and body, imprinted with TEVA over 8229 on both cap and body in black ink. Available as follows:\n                  Bottles of 28 capsules: NDC 0093-8229-28\n                  50 mg capsules\n                  Hard gelatin capsule with light brown opaque cap and body, imprinted with TEVA over 8231 on both cap and body in black ink. Available as follows:\n                  Bottles of 28 capsules: NDC 0093-8231-28\n                  Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F); excursions permitted to 15\u00b0 to 30\u00b0C (59\u00b0 to 86\u00b0F) [see USP Controlled Room Temperature].",
    "adverseReactions_original": "None."
}